Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$3.09 -3.18%

-$0.16 today

Market cap
$72.48M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.15M

Average 0.16M

COYA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Coya Therapeutics, Inc.NASDAQ: COYA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns positive

Q1 FY2026 gross profit was $248.34K, compared with -$4.96M a year earlier. Trailing-twelve-month gross profit was $7.92M.

Context

  • Gross profit amounted to 99.7% of revenue in FY2025, down 134.2 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $248.34K or moves back toward the trailing-twelve-month quarterly average of $1.98M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$248.34K-93.7% QoQ
Last fiscal yearDec 2025
$7.92M+195.3% YoY
LTMMar 2026
$7.92M+177.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+105.0%——
1 year+195.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
7.92M USD
Year-over-year change
+195.3%

Gross Profit vs competitors

How COYA compares with its peers on the latest reported figures

  • COYA's LTM Mar 2026 gross profit of $7.92M is the 2nd highest of the 11 companies compared; the peer median is -$125.88K.
  • Its year-over-year change of +177.2% is the 2nd highest of 9, against a peer median of -5.9%.
  • Gross profit amounts to 99.8% of revenue for COYA, versus a peer median of 90.8%.
COYA Competitors Peer median
Gross Profit for COYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M +16.2%-9.3%69.9%
COYACoya Therapeutics, Inc.LTM Mar 2026$7.92M +177.2%—99.8%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.09M +1193.2%+66.6%99.5%
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$5K +100.0%——
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.17K ———
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026-$121K +2.4%-83.1%—
IMMXImmix Biopharma, Inc.LTM Mar 2026-$130.77K ———
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$151K -100.6%——
CLNNClene Inc.LTM Mar 2026-$244K -188.4%-29.4%182.1%
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$711K -14.3%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K -146.7%—82.0%
Peer median (excluding COYA) -$125.88K-5.9%-19.4%90.8%

Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006M3.55M7.95M
Cost of Revenue04.41M5.5M11.87M27.36K
Gross Profit0(4.41M)500.68K(8.31M)7.92M
Gross Margin——8.3%-233.9%99.7%
Research & Development2.54M4.94M6.04M11.89M16.73M
Selling, General & Admin2.31M4.85M7.83M8.89M11.45M
Operating Expenses4.87M5.4M8.4M8.94M28.18M
Depreciation & Amortization16.13K27.36K27.36K27.36K27.36K
EBITDA(4.88M)(9.26M)(7.33M)(17.2M)(21.2M)
EBITDA Margin——-122.2%-483.9%-266.8%
Operating Income(4.87M)(9.81M)(7.9M)(17.25M)(20.27M)
Operating Margin——-131.7%-485.4%-255.0%
Interest Income00000
Interest Expense00000
Other Income / Expenses(21.48K)(2.43M)639.37K1.65M(957.4K)
Income Before Tax(4.89M)(12.24M)(7.26M)(15.6M)(21.22M)
Pre-Tax Margin——-121.0%-439.0%-267.1%
Income Tax Expense00723.85K(720.29K)3.09K
Net Income(4.89M)(12.24M)(7.99M)(14.88M)(21.23M)
Net Margin——-133.1%-418.7%-267.1%
EPS (Basic)(0.74)(1.23)(0.79)(0.98)(1.27)
EPS (Diluted)(0.74)(1.23)(0.79)(0.98)(1.27)
Weighted Avg Shares6.6M9.95M10.16M15.24M16.73M
Weighted Avg Shares (Diluted)6.6M9.95M10.16M15.24M16.73M

Coya Therapeutics, Inc.

NASDAQ:COYA

Intrinsic Alpha fair value

Locked

Current Price

$3.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.